Search
Amifampridine
go.drugbank.com/drugs/DB11640ApprovedThis leads to the reduction of the compound muscle action potential (CMAP) [A33863]. … Reduced acetylcholine release at the neuromuscular junction leads to decreased frequency of miniature endplate potentials of normal amplitude, and insufficient acetylcholine levels for the activation of
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase
Dimethicone 410
go.drugbank.com/drugs/DB14005Approved[L2162] The name dimethicone has a lot of nomenclature inconsistencies as it is used to refer to common names, generic names, trade names or even for the listing of mixtures. … It is reported that the term dimethicone includes the notation of polydimethylsiloxane and trimethylsiloxy-terminated fluids between 20-30,000 cSt (viscosity).[L2163]
Metronidazole
go.drugbank.com/drugs/DB00916ApprovedInvestigationalMetronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. … It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Products: ABXEDA EAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalIn addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Ublituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[L44508] The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.[L47486] … [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012.
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalIn the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Synonyms: t-PA, t-plasminogen activatorSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.
Nitroglycerin
go.drugbank.com/drugs/DB00727ApprovedInvestigational[L42445] It is also used to induce intraoperative hypotension.[L7099] … [A180166,A180172] Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina.[A249970] Nitroglycerin causes vasodilation in both arteries and veins.
Products: NITROGLICERINA PH&T